PEG-IL2 Combination Therapy for Treg-Mediated Atopic Dermatitis Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for atopic dermatitis are limited in efficacy, duration, and safety, and there is a need for a treatment that effectively upregulates regulatory T cells (Tregs) to restore immune balance and prevent chronic relapse.
Innovation Solution
A pharmaceutical composition comprising polyethylene glycol-modified interleukin 2 (PEG-IL2), a glucocorticoid, and small molecular weight hyaluronic acid (HA) is administered to upregulate Tregs and restore immune balance in the skin, enhancing their immunosuppressive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PEG-modified IL-2 is used to promote Treg cell proliferation, then the immunomodulatory efficacy is improved, but the device complexity increases due to protein modification
Solution Approach 1:
The patent modifies IL-2 by conjugating polyethylene glycol (PEG) chains with different molecular weights to the N-terminal amino group, changing the physical and chemical parameters of the protein. This parameter change increases the half-life and stability of IL-2 while reducing immunogenicity, thereby improving immunomodulatory efficacy without fundamentally altering the biological function
Solution Approach 2:
The patent creates a composite structure by combining IL-2 protein with PEG polymer chains. This composite material approach allows the retention of IL-2's biological activity while adding the beneficial properties of PEG (increased circulation time, reduced clearance), resolving the contradiction between efficacy improvement and complexity increase
2Reliability
If high concentration IL-2 is used to promote Teff cell proliferation, then the immune response is enhanced, but the therapeutic safety deteriorates due to excessive immune activation
Solution Approach 1:
The patent exploits the differential expression of IL-2 receptors on different T cell subsets. Treg cells express high levels of CD25 (IL-2Rα), while Teff cells express lower levels. By using PEG-IL-2 at optimized concentrations, the therapy achieves local quality differentiation in immune activation, preferentially expanding Treg cells while minimizing Teff cell proliferation, thus enhancing safety without sacrificing efficacy
3Ease of operation
If traditional treatments are used for atopic dermatitis, then the treatment simplicity is maintained, but the therapeutic efficacy deteriorates with limited duration and high relapse rate
Solution Approach 1:
The patent employs PEG-IL-2 to pre-expand and activate regulatory T cells before they are administered to patients with atopic dermatitis. This preliminary action of ex vivo expansion ensures that a sufficient number of functional Treg cells are available for immediate therapeutic effect, thereby improving efficacy while maintaining the simplicity of the overall treatment protocol
Solution Approach 2:
The PEG modification of IL-2 extends the half-life of the cytokine in circulation, enabling continuous immunomodulatory activity. This continuity of useful action ensures sustained Treg cell proliferation and function, preventing disease relapse and improving long-term therapeutic efficacy without requiring frequent administrations
Data Source
Figure 1a~1b
Figure 1c
Figure 1d
AI summary
Disclosed in the present invention is a pharmaceutical composition for treating atopic dermatitis, the pharmaceutical composition comprising polyethylene glycol-modified interleukin 2, a glucocorticoid and low-molecular-weight hyaluronic acid, and optionally comprising a pharmaceutically acceptable carrier; and further provided is 10KD PEG-modified IL2 and the use thereof in treating type I allergic diseases.